Study S000665

The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03878706
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 240
Start: 2017-11-03
Primary completion: 2026-12-31
Lead sponsor: University of Athens
Conditions: Diabetes Mellitus, Type 2
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Comparison of Global Longitudinal Strain (GLS) difference among treatment groups. [12 months]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007779	Myocardial deformation links combined liraglutide-empagliflozin therapy with improved cardiovascular and economic outcomes in type 2 diabetes: a 6-year study. Thymis J, European heart journal. Imaging methods and practice	2026	Other	PMID 42226732 DOI	cites ClinicalTrials.gov:NCT03878706; registry reference DERIVED:42226732
R0002970	Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes. Ikonomidis I, Journal of the American Heart Association	2025	Nonrandomized study	PMID 40008510 DOI	cites ClinicalTrials.gov:NCT03878706; registry reference DERIVED:40008510
R0008057	Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment. Ikonomidis I, Journal of the American Heart Association	2020	Randomized trial	PMID 32326806 DOI	cites ClinicalTrials.gov:NCT03878706; registry reference DERIVED:32326806
R0021793	Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Frías JP, The lancet. Diabetes & endocrinology	2016	Randomized trial	PMID 27651331 DOI	registry reference RESULT:27651331
R0022060	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27295427 DOI	registry reference RESULT:27295427
R0013881	User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Shaefer CF, Postgraduate medicine	2015	Narrative review	PMID 26371721 DOI	registry reference RESULT:26371721
R0017997	Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. van Bloemendaal L, The Journal of endocrinology	2014	Narrative review	PMID 24323912 DOI	registry reference RESULT:24323912